Nigeria is set to receive Lenacapavir, a new long-acting HIV prevention drug, in March 2026, the federal government has announced. The National Agency for the Control of AIDS (NACA) confirmed preparations for its introduction as a pre-exposure prophylaxis (PrEP) option.
The drug, administered as an injection twice a year, has shown near-complete protection against HIV in clinical trials. The phased rollout will initially target ten states, including Lagos, Kano, and FCT, prioritising areas with readiness for effective service delivery.
Healthcare workers have been trained nationwide to safely administer Lenacapavir, while information and awareness campaigns are being launched to ensure public understanding and demand. NAFDAC approval ensures the drug meets regulatory and quality standards.
Officials say Lenacapavir represents a major advancement in HIV prevention, offering a convenient, long-lasting option to reduce new infections. The government called on stakeholders to support the programme and expand access to this breakthrough tool.
